Compare DexCom, Inc. (DXCM) vs Vanguard Total World Stock Index Fund ETF (VT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard Total World Stock Index Fund ETF — how do they compare? DexCom, Inc. trades at $77.28 (market cap $28.06B), while Vanguard Total World Stock Index Fund ETF trades at $156. The key difference: Vanguard Total World Stock Index Fund ETF is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | VT | |
|---|---|---|
Market Cap | $28.06B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $89.53 | $159.35 |
52-Week Low | $54.84 | $128.41 |
Enterprise Value | $27.03B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
The Vanguard Total World Stock ETF (VT) trades at $156.24, down 0.34% on the day. Technical indicators show a bullish trend from moving averages, with neutral oscillators suggesting consolidation near key support at $155. The fund provides global equity diversification with over 10,000 holdings across developed and emerging markets, maintaining a low expense ratio of 0.06%.
VT offers comprehensive global exposure but faces competition from lower-cost alternatives. The fund's broad diversification reduces single-country risk, though its performance remains tied to global economic conditions. A dividend of $0.56 per share is scheduled for payment on June 23, 2026, providing income alongside growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard Total World Stock Index Fund ETF
VT is a foundational, low-cost ETF that seeks to track the FTSE Global All Cap Index, providing exposure to nearly 10,000 stocks across developed and emerging markets worldwide, including the United States. It serves as a single-ticker solution for total global equity diversification, capturing approximately 98% of the world's investable market capitalization.
Read more on VT →
